Vasopharm is a leading brand that specializes in the development and production of innovative pharmaceutical products. With a strong focus on neuroprotection, Vasopharm's flagship product, Ronopterin, is the first and only selective inhibitor of inducible Nitric Oxide Synthase (iNOS) to demonstrate repeated signs of biochemical and clinical neuroprotection in patients with traumatic brain injury (TBI). Ronopterin has shown promising results in reducing brain glutamate, improving neurological outcomes, and enhancing the quality of life for TBI patients.

Vasopharm's management team, with their extensive experience in biopharma and clinical research, ensures the highest standards of quality and efficacy in their products. Supported by a dedicated group of investors, Vasopharm is committed to providing cost-effective solutions and making a positive impact in the field of neuroprotection. With a clear regulatory pathway and ongoing clinical trials, Vasopharm aims to expand the application of Ronopterin to other indications with high unmet medical needs